The global HER2-positive gastric cancer treatments market is expected to grow at a compound annual growth rate (CAGR) of 3.5%, with a current valuation of US$ 1261.8 million by 2023. Healthcare technology advancements are expected to drive the market to US$1779.8 million by 2033.
The market for gastric cancer that is HER2-positive will likely experience rapid expansion as more people become aware of the symptoms and causes of the illness.The market is expected to develop due to an increase in product releases and approvals, as well as increased business activity in conducting clinical trials to find effective treatments for patients with stomach cancer that is HER2 positive.
For instance, in January 2021, the U.S. FDA approved Enhertu, an antibody-drug conjugate product, to treat HER-2 positive stomach cancers that have spread. Additionally, it is projected that the market’s growth would be aided by the increasing number of drugs in the pipeline that are gaining special designations.
Reveal Patterns With Your Sample Report Preview:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16232
North America dominates the HER 2 positive gastric cancer market due to the presence of key market players’ presence, along with recent product launches and established healthcare infrastructure, which will accelerate the market’s growth in the region. The significant R&D investments in Europe abode well for market growth.
Key Takeaways from the Market Study
- As of 2023, the HER2 positive gastric cancer market was valued at US$ 1261.8 Million
- From 2023 to 2033, the HER2 positive gastric cancer industry is poised to grow at an 3.5% CAGR
- By 2033, the HER2 positive gastric cancer market is slated to reach a valuation of US$ 1779.8Million
- Based on therapy, the targeted therapy segment dominated the global market in 2023 with a revenue share of over 55.4%.
- China is poised to yield a CAGR of 3.2% with respect HER2 positive gastric cancer in 2033
“Technological advancement in healthcare and increase in the prevalence of gastric cancer is expected to radically transform the HER 2 positive gastric cancer market in the coming years,” comments an analyst at FMI.
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16232
Competitive Landscape
- AstraZeneca
- Bayer
- Bristol-Myers Squibb
- Ono Pharmaceutical Co. Ltd
- Hutchison Medipharma
- LintonPharm
- Shanghai Henlius Biotech
- Sanofi
- Pfizer
- Novartis AG
Manufacturers and players functional in the global HER 2 positive gastric cancer market are adopting various corporate growth strategies such as new product launches, mergers and acquisitions, and geographical expansion, among others.
- In September 2022 -Shanghai Henlius Biotech, Inc announced a phase 1 clinical trial of the company’s HLX22, an anti-human epidermal growth factor receptor-2 (HER2) humanised monoclonal antibody(mAb) injection, has been completed in patients with HER2 overexpressing advanced solid tumours. The results of this study demonstrated the good safety and tolerability of HLX22.
- In January 2022 — LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that it has completed the enrollment of stage 1 of the global phase III trial (clinicaltrials.gov: NCT04222114). This trial evaluates the safety and efficacy of Catumaxomab, a bispecific monoclonal antibody, in adult patients with advanced Gastric Cancer with Peritoneal Carcinomatosis (GCPC).
Key Segments Covered in HER2 Positive Gastric Cancer Industry Survey
HER2 Positive Gastric Cancer Market by Therapy:
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Targeted Therapy
HER2 Positive Gastric Cancer Market by Stage:
- Stage I
- Stage II
- Stage III
- Stage IV
HER2 Positive Gastric Cancer Market by End-User:
- Ambulatory surgery centres,
- Hospitals and Specialty clinics
- Others
Unlock In-Depth Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16232
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube